

Investor News

July 17, 2008

Birgit Grund
Senior Vice President
Investor Relations

Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2485
F +49 6172 608-2488
birgit.grund@fresenius.com
www.fresenius.com

Strong financial results in the first half of 2008

Below, Fresenius provides an overview on the financial results of the first half of 2008:

Based on preliminary figures, Group sales increased 9 % in constant currency and by 2 % at actual rates to € 5,710 million. Group EBIT rose by 8 % in constant currency. At actual rates, EBIT was at previous year's level of € 780 million. Group net income grew by 13 % in constant currency and by 8 % at actual rates to € 211 million.

Below are the financial results by business segment, based on preliminary figures:

Fresenius Medical Care achieved sales growth of 10 % to US\$ 5,177 million. EBIT rose 8 % to US\$ 816 million. Net income grew by 17 % to US\$ 395 million.

Fresenius Kabi achieved an excellent sales growth of 14 % to € 1,121 million. EBIT increased by 14 % to € 181 million. The EBIT margin was 16.1 % (H1 2007: 16.1 %).

Fresenius Helios achieved strong sales and EBIT growth. Sales increased by 17 % to € 1,040 million. EBIT grew by 22 % to € 83 million.

Fresenius Vamed achieved sales growth of 11 % to € 177 million. EBIT was € 9 million.

The final figures for the first half of 2008 and the outlook for the full year will be provided on July 30, 2008, as originally scheduled.

Key figures of the business segments (US GAAP, preliminary)

in € million	H1 2008	H1 2007	actual rates	Change constant currency
Sales				
Fresenius Medical Care	3,382	3,554	-5%	6%
Fresenius Kabi	1,121	986	14%	17%
Fresenius Helios	1,040	890	17%	17%
Fresenius Vamed	177	160	11%	11%
Corporate / Other	-10	2	--	--
Fresenius Group	5,710	5,592	2%	9%
EBIT				
Fresenius Medical Care	533	568	-6%	4%
Fresenius Kabi	181	159	14%	16%
Fresenius Helios	83	68	22%	22%
Fresenius Vamed	9	9	0%	0%
Corporate / Other	-26	-24	-8%	-8%
Fresenius Group	780	780	0%	8%

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approx. € 11.4 billion. On March 31, 2008 the Fresenius Group had 116,203 employees worldwide.

For more information visit the Company's website at www.fresenius.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Board of Management: Dr. Ulf M. Schneider (President and CEO), Rainer Baule, Dr. Francesco De Meo, Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst Wastler
 Supervisory Board: Dr. Gerd Krick (Chairman)
 Registered Office: Bad Homburg, Germany/Commercial Register No. HRB 10660